DEVELOPMENT OF A DENGUE VACCINE

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 目的：开发登革热病毒疫苗。 登革热病毒威胁着世界三分之一以上的人口，估计每年导致 100 - 1.5 亿登革热病例。 InViragen 的登革热疫苗是由美国疾病控制与预防中心 (CDC) 的合作者设计的，旨在预防所有四种登革热病毒。该疫苗已在临床前动物模型中被证明是安全有效的。 我们建立了非人类灵长类动物模型来测试用于人类临床开发的实验性登革热疫苗。我们正在探索嵌合四价疫苗的临床前开发。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: To develop a vaccine for dengue viruses. Dengue viruses threaten over a third of the world's population and cause an estimated 100 - 150 million cases of dengue fever every year. InViragen's dengue vaccine was designed by collaborators at the Centers for Disease Control and Prevention (CDC) to protect against all four of the dengue viruses. The vaccine has been shown to be safe and effective in preclinical animal models. We have set up nonhuman primate animal models to test an experimental dengue vaccine for human clinical development. We are exploring preclinical development of a chimeric tetravalent vaccine.